Differential inhibition by alpha-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices.
The presynaptic nicotinic modulation of dopamine release from striatal nerve terminals is well established, but the subtype(s) of neuronal nicotinic acetylcholine receptor (nAChR) underlying this response has not been identified. Recently, alpha-conotoxin-MII has been reported to inhibit potently and selectively the rat alpha3beta2 combination of nAChR subunits. Here we have synthesised the peptide, confirmed its specificity, and examined its effect on the (+/-)-anatoxin-a-evoked release of [3H]dopamine from rat striatal synaptosomes and slices. Alpha-conotoxin-MII (112 nM) completely blocked acetylcholine-evoked currents of alpha3beta2 nAChRs expressed in Xenopus oocytes (IC50 = 8.0 +/- 1.1 nM). Pairwise combinations of other nicotinic subunits were not blocked by 112 nM alpha-conotoxin-MII. On perfused striatal synaptosomes and slices, alpha-conotoxin-MII dose-dependently inhibited [3H]dopamine release evoked by 1 microM (+/-)-anatoxin-a with IC50 values of 24.3 +/- 2.9 and 17.3 +/- 0.1 nM, respectively. The dose-response curve was shifted to the right with increasing agonist concentrations. However, the maximal inhibition of responses achieved by alpha-conotoxin-MII (112 nM) was 44.9 +/- 5.4% for synaptosomes and 25.0 +/- 4.1% for slices, compared with an inhibition by 10 microM mecamylamine of 77.9 +/- 3.7 and 88.0 +/- 2.1%, respectively. These results suggest the presence of presynaptic alpha3beta2-like nAChRs on striatal dopaminergic terminals, but the incomplete block of (+/-)-anatoxin-a-evoked [3H]dopamine release by alpha-conotoxin-MII also supports the participation of nAChRs composed of other subunits. The lower inhibition found in slices is consistent with an additional indirect nicotinic stimulation of dopamine release via an alpha-conotoxin-MII-insensitive nAChR.
Kaiser
S A
SA
Department of Biology and Biochemistry, University of Bath, England, UK.
Soliakov
L
L
Harvey
S C
SC
Luetje
C W
CW
Wonnacott
S
S
D000818:Animals; D001427:Bacterial Toxins / Q000494:pharmacology; D020916:Conotoxins; D003342:Corpus Striatum / Q000737:chemistry / Q000378:metabolism*; D000087522:Cyanobacteria Toxins; D004298:Dopamine / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D008297:Male; D008387:Marine Toxins / Q000494:pharmacology; D052998:Microcystins; D008978:Mollusk Venoms / Q000494:pharmacology*; D009498:Neurotoxins / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D009865:Oocytes / Q000502:physiology; D009924:Organ Culture Techniques; D010455:Peptides / Q000494:pharmacology*; D017729:Presynaptic Terminals / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000737:chemistry / Q000378:metabolism; D014316:Tritium; D014326:Tropanes; D014982:Xenopus laevis
D001427:Bacterial Toxins; D020916:Conotoxins; D000087522:Cyanobacteria Toxins; D008387:Marine Toxins; D052998:Microcystins; D008978:Mollusk Venoms; D009498:Neurotoxins; D018733:Nicotinic Antagonists; D010455:Peptides; D014326:Tropanes; C098872:alpha-conotoxin MII; D014316:Tritium; C509783:anatoxin a; D004298:Dopamine